Finerenone was recently found to reduce the risk of clinically important kidney outcomes in #CKD patients with type 2 diabetes. Have a look at this FIDELITY trial analysis to learn more.
Click on the image to download the infographic.
The ISN Academy is committed to delivering high-quality educational resources to... read more
The ISN recognizes the importance of global research initiatives in advancing... read more
The “ISN Global Kidney Trials Insights: A Guide for Everyone”... read more
The ISN is pleased to announce the signing of a new... read more
Kidney International® Patients With Crush Syndrome and Kidney Disease: Lessons Learned From... read more
Staff from Dalal Jamm Hospital and Cliniques Universitaires St. Luc during... read more
In 2024, the ISN welcomed new Affiliated and Collective-member societies, extending... read more
The #ISNWCN Social Media Team will be on hand at WCN’25... read more
The 2024 ISN leadership elections are underway from November 4 to... read more
Calling all early-career researchers! Have you published original research in Kidney International®... read more
